Market Research Logo

Hemochromatosis - Pipeline Review, H2 2018

Hemochromatosis - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemochromatosis - Pipeline Review, H2 2018, provides an overview of the Hemochromatosis (Gen


Introduction
Global Markets Direct Report Coverage
Hemochromatosis - Overview
Hemochromatosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hemochromatosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hemochromatosis - Companies Involved in Therapeutics Development
Ionis Pharmaceuticals Inc
La Jolla Pharmaceutical Company
Protagonist Therapeutics Inc
Silence Therapeutics Plc
Vifor Pharma AG
Hemochromatosis - Drug Profiles
BBI-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Replace Hepcidin for Iron Overload Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONISTMPRSS-6LRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJPC-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTG-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLN-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIT-2763 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hemochromatosis - Dormant Projects
Hemochromatosis - Product Development Milestones
Featured News & Press Releases
Feb 08, 2018: Vifor Pharma Ferroportin Inhibitor Enters Phase-I Clinical Trial
Dec 18, 2017: La Jolla Announces Initiation of Multicenter, Randomized, Phase II Clinical Study of LJPC-401 in Patients with Hereditary Hemochromatosis
Sep 07, 2016: La Jolla Pharmaceutical Company Reports Positive Results from Phase 1 Study of LJPC-401
Jul 28, 2016: Protagonist Therapeutics Receives SBIR Funding for the Development of Injectable Hepcidin Mimetics for Treatment of Iron Overload Disorders
Oct 19, 2015: La Jolla Pharmaceutical Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload
Aug 11, 2015: La Jolla Pharmaceutical Company Announces FDA Acceptance of IND for LJPC-401
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hemochromatosis, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Hemochromatosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Hemochromatosis - Pipeline by La Jolla Pharmaceutical Company, H2 2018
Hemochromatosis - Pipeline by Protagonist Therapeutics Inc, H2 2018
Hemochromatosis - Pipeline by Silence Therapeutics Plc, H2 2018
Hemochromatosis - Pipeline by Vifor Pharma AG, H2 2018
Hemochromatosis - Dormant Projects, H2 2018
List of Figures
Number of Products under Development for Hemochromatosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report